[1] dos SSI, Swerdlow AJ.Thyroid cancer epidemiology in England and Wales:time trends and geographical distribution[J].Br J Cancer, 1993, 67(2):330-340.
[2] Pettersson B, Adami HO, Wilander E, et al.Trends in thyroid cancer incidence in Sweden, 1958-1981, by histopathologictype[J].Int J Cancer, 1991, 48(1):28-33.
[3] 国兰兰, 高沁怡, 李亚明, 等.影响分化型甲状腺癌术后131I治疗疗效的因素[J].中国医学影像技术, 2011, 27(5):926-929.
Gao LL, Gao QY, Li YM, et al.Impact factors of therapeutic effect of 131I scintigraphy treatment for differentiated thyroid cancer after operation[J].Chin J Med Imaging Technol, 2011, 27(5):926-929.
[4] Mallick U, Harmer C, Yap B, et al.Ablation with low-dose radioiodine and thyrotropinalfa in thyroid cancer[J].N Engl J Med, 2012, 366(18):1674-1685. DOI:10.1056/NEJMoa1109589.
[5] Schlumberger M, Catargi B, Borget I, et al.Strategies of radioiodine ablation in patients with low-risk thyroid cancer[J].N Engl J Med, 2012, 366(18):1663-1673. DOI:10.1056/NEJMoa1108586.
[6]

潘中允.放射性核素治疗学[M].北京:人民卫生出版社, 2006.

Pan ZY.Radionuclide therapy[M].Beijing:People's Medical Publishing House, 2006.
[7] 中华医学会核医学分会.131I治疗分化型甲状腺癌指南(2014版)[J].中华核医学与分子影像杂志, 2014, 34(4):264-278. DOI:10.3760/cma.j.issn.2095-2848.2014.04.002.
Chinese Society of Nuclear Medical.131I treatment of differentiated thyroid carcinoma Directory(2014 Edition)[J].Chin J Nucl Med Mol Imaging, 2014, 34(4):264-278.  doi: 10.3760/cma.j.issn.2095-2848.2014.04.002
[8] Sciuto R, Romano L, Rea S, et al.Natural history and clinical outcome of differentiated thyroid carcinoma:a retrospective analysis of 1503 patients treated at a single institution[J].Ann Oncol, 2009, 20(10):1728-1735. DOI:10.1093/annonc/mdp050.
[9] Eustatia-Rutten CF, Corssmit EP, Biermasz NR, et al.Survival and death causes in differentiated thyroid carcinoma[J].J Clin Endocrinol Metab, 2006, 91(1):313-319. DOI:10.1210/jc.2005-1322.
[10] Baudin E, Schlumberger M.New therapeutic approaches for metas-tatic thyroid carcinoma[J].Lancet Oncol, 2007, 8(2):148-156. DOI:10.1016/S1470-2045(07)70034-7.
[11] Durante C, Haddy N, Baudin E, et al.Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma:benefits and limits of radioiodine therapy[J].J Clin Endocrinol Metab, 2006, 91(8):2892-2899. DOI:10.1210/jc.2005-2838.
[12] Mazzaferri EL, Kloos RT.Clinical review 128:Current approaches to primary therapy for papillary and follicular thyroid cancer[J].J Clin Endocrinol Metab, 2001, 86(4):1447-1463. DOI:10.1210/jcem.86.4.7407.
[13] Haugen BR, Alexander EK, Bible KC, et al.2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer:The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer[J].Thyroid, 2016, 26(1):1-133. DOI:10.1089/thy.2015.0020.
[14] 傅宏亮, 杜学亮, 顾振辉, 等.分化型甲状腺癌131I疗效影响因素分析[J].上海交通大学学报:医学版, 2010, 30(3):249-252.
Fu HL, Du XL, Gu ZH, et al.Analysis of influential factors for efficacy of 131I thyroid remnant ablation for differentiated thyroid carcinoma[J].J shanghai Jiaotong Univ(Med Sci), 2010, 30(3):249-252.
[15] 刘晔, 晋建华, 刘建中, 等.放射性131I去除分化型甲状腺癌术后残留甲状腺组织的疗效与影响因素分析[J].中国药物与临床, 2013, 13(5):556-558. DOI:10.11655/zgywylc2013.05.003.
Liu Y, Jin JH, Liu JZ, et al.Efficacy and influencing factors of radioactive 131I for elimination of thyroid remnants following differentiated thyroid carcinoma resection[J].Chin RemedClin, 2013, 13(5):556-558.  doi: 10.11655/zgywylc2013.05.003
[16] Sánchez R, Espinosa-de-los-Monteros AL, Mendoza V, et al.Adequate thyroid-stimulating hormone levels after levothyroxine discontinuation in the follow-up of patients with well-differentiated thyroid carcinoma[J].Arch Med Res, 2002, 33(5):478-481.  doi: 10.1016/S0188-4409(02)00394-6
[17] Liel Y.Preparation for radioactive iodine administration in differentiated thyroid cancer patients[J].Clin Endocrinol(Oxf), 2002, 57(4):523-527. DOI:10.1046/j.1365-2265.2002.01631.x.
[18] Mashego MR, Wu L, Van Dam JC, et al.MIRACLE:mass isotopomer ratio analysis of U-13C-labeled extracts.A new method for accurate quantification of changes in concentrations of intracellular metabolites[J].BiotechnolBioeng, 2004, 85(6):620-628. DOI:10.1002/bit.10907.
[19]

匡安仁.131I治疗分化型甲状腺癌[M].北京:人民卫生出版社, 2013.

Kuang AR.131I treatment of differentiated thyroid carcinoma[M].Beijing:People's Medical Publishing House, 2013.
[20]

MäenpääHO, Heikkonen J, Vaalavirta L, et al.Low vs.high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study[J/OL].PLoS One, 2008, 3(4): e1885[2016-06-28].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2270902/. DOI: 10.1371/journal.pone.0001885.
[21] Schlumberger M, Catargi B, Borget I, et al.Strategies of radioiodine ablation in patients with low-risk thyroid cancer[J].N Engl J Med, 2012, 366(18):1663-1673. DOI:10.1056/NEJMoa1108586.
[22] Mallick U, Harmer C, Yap B, et al.Ablation with low-dose radioiodine and thyrotropinalfa in thyroid cancer[J].N Engl J Med, 2012, 366(18):1674-1685. DOI:10.1056/NEJMoa1109589.